Lupin’s Europe business recorded strong growth of 20% with sales of Rs.5,400 million during the year. As part of our strategic vision, we have a strong focus on building a Specialty products portfolio while continuing to grow our Generics business in the region. On the Generic side, we continue to build on a meaningful portfolio of niche products while extending and deepening the relationships with our strategic partners within Europe. Our Specialty play in the Neurology space for the European region will further enhance the value of our business.
In Germany, our emphasis continues on balancing the mix of Generics and Specialty products, particularly in Neurology, where we achieved a substantial sales growth of 18% as compared to FY2017. We continue to invest in creating a quality pipeline for the European markets.
We filed two marketing authorization applications with the EU Authorities, having received five approvals during FY2018. At present, the cumulative filings for Europe stand at 62 with 59 approvals to date.